3
Announcements
Trials
Browse
Landscape
Status
Available
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
53
Observational
21
Expanded_access
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Multiple Myeloma
32
Recurrence
10
Lymphoma, Non-Hodgkin
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Lymphoma, Large B-Cell, Diffuse
2
Leukemia, Myeloid, Acute
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Hodgkin Disease
2
Granuloma, Plasma Cell
2
Waldenstrom Macroglobulinemia
1
Sarcoma
1
Primary Myelofibrosis
1
Precancerous Conditions
1
Neoplasms, Plasma Cell
1
Myelodysplastic Syndromes
1
Monoclonal Gammopathy of Undetermined Significance
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Follicular
1
Lymphoma, Extranodal NK-T-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Leukemia, Promyelocytic, Acute
1
Leukemia, Plasma Cell
1
Leukemia, Myelomonocytic, Acute
1
Leukemia, Myeloid, Accelerated Phase
1
Leukemia, Monocytic, Acute
1
Leukemia, Megakaryoblastic, Acute
1
Interventions
venetoclax
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Expanded_access
×
Amyloidosis
×
Plasma cell
×
Clear all
NCT03123029
2026-01-30
Expanded Access to Venetoclax
AbbVie
Available